000			03711nam a22004455i 4500
001			u371622
003			SIRSI
005			20160812080138.0
007			cr nn 008mamaa
008			110110s2010 xxu| s |||| 0|eng d
020			_a9781441963062 _9978-1-4419-6306-2
040			_cMX-MeUAM
050		4	_aR-RZ
082	0	4	_a610 _223
100	1		_aRaffa, Robert B. _eeditor.
245	1	0	_aChemo Fog _h[recurso electrónico] : _bCancer Chemotherapy-Related Cognitive Impairment / _cedited by Robert B. Raffa, Ronald J. Tallarida.
264		1	_aNew York, NY : _bSpringer New York : _bImprint: Springer, _c2010.
300			_aXXI, 216 p. _bonline resource.
336			_atext _btxt _2rdacontent
337			_acomputer _bc _2rdamedia
338			_aonline resource _bcr _2rdacarrier
347			_atext file _bPDF _2rda
490	1		_aAdvances in Experimental Medicine and Biology, _x0065-2598 ; _v678
505	0		_aShort Introduction and History -- Patient’s Perspective -- Oncology Nurse’s Perspective -- Oncology Pharmacist’s Perspective -- The Impact of Chemo Brain on the Patient with a High-Grade Glioma -- Neurocognitive Effects of Childhood Cancer Treatment -- The Economic Burden -- Designing Conceptual Model-Based Research in Chemotherapy-Related Changes in Cognitive Function -- Neuropsychologic Testing for Chemotherapy-Related Cognitive Impairment -- Imaging as a Means of Studying Chemotherapy-Related Cognitive Impairment -- Chemotherapy Associated Central Nervous System Damage -- Is Systemic Anti-Cancer Therapy Neurotoxic? Does Chemo Brain Exist? And Should We Rename It? -- Evaluation of Multiple Neurotoxic Outcomes in Cancer Chemotherapy -- Chemotherapy-Related Visual System Toxicity -- The Possible Role of Cytokines in Chemotherapy-Induced Cognitive Deficits -- Pharmacokinetics of Anti-Cancer Drugs Used in Breast Cancer Chemotherapy -- Combination Analysis -- Animal Models -- Chemo Brain (Chemo Fog) as a Potential Side Effect of Doxorubicin Administration: Role of Cytokine-Induced, Oxidative/Nitrosative Stress in Cognitive Dysfunction -- Effects of 5-FU -- Future Directions.
520			_aCancer patients have benefitted greatly from recent advances in the drugs, dose regimens, and combinations used to treat their primary tumor and for the treatment or prevention of spread of their disease. Due to the advances in chemotherapy and other aspects of prevention, early detection, and treatment modalities, an increasing percentage of patients are surviving the disease. For some types of cancer, the majority of patients live decades beyond their diagnosis. For this they are forever thankful and appreciative of the drugs that helped lead to this increased survival rate. But no drug is devoid of adverse effects. This also applies to chemotherapeutic agents. The acute cytotoxic effects of these agents are well known––indeed are often required for their therapeutic benefit. The chronic adverse effects are varied and in some cases less well known. With the increase in survival rates, there has emerged a new awareness of these chronic adverse effects.
650		0	_aMedicine.
650		0	_aOncology.
650	1	4	_aBiomedicine.
650	2	4	_aBiomedicine general.
650	2	4	_aCancer Research.
700	1		_aTallarida, Ronald J. _eeditor.
710	2		_aSpringerLink (Online service)
773	0		_tSpringer eBooks
776	0	8	_iPrinted edition: _z9781441963055
830		0	_aAdvances in Experimental Medicine and Biology, _x0065-2598 ; _v678
856	4	0	_zLibro electrónico _uhttp://148.231.10.114:2048/login?url=http://link.springer.com/book/10.1007/978-1-4419-6306-2
596			_a19
942			_cLIBRO_ELEC
999			_c199502 _d199502